NCT04169698View on ClinicalTrials.gov

Alendronate Versus Denosumab in Kidney Transplant Patients

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 17, 2019

Primary Completion Date

May 1, 2021

Study Completion Date

May 1, 2021

Conditions
Osteoporosis, OsteopeniaRenal Transplant Recipient
Interventions
DRUG

Denosumab 60 mg/ml [Prolia]

full length human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand

DRUG

Alendronate 70Mg Tab

Bisphosphonates

Trial Locations (1)

11566

National institute of urology and nephrology, Cairo

All Listed Sponsors
collaborator

Nahda University

OTHER

lead

Ain Shams University

OTHER

NCT04169698 - Alendronate Versus Denosumab in Kidney Transplant Patients | Biotech Hunter | Biotech Hunter